A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cel Sci Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 27,100 shares of CVM stock, worth $17,073. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,100
Previous 16,600 63.25%
Holding current value
$17,073
Previous $19,000 47.37%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.05 - $1.5 $9,716 - $13,881
-9,254 Reduced 25.37%
27,220 $28,000
Q2 2024

Aug 14, 2024

BUY
$1.11 - $1.85 $1,032 - $1,720
930 Added 2.62%
36,474 $42,000
Q1 2024

May 15, 2024

SELL
$1.63 - $3.08 $17,884 - $33,793
-10,972 Reduced 23.59%
35,544 $67,000
Q4 2023

Feb 14, 2024

BUY
$1.07 - $3.07 $2,847 - $8,169
2,661 Added 6.07%
46,516 $126,000
Q3 2023

Nov 14, 2023

BUY
$1.17 - $2.86 $21,157 - $51,717
18,083 Added 70.17%
43,855 $54,000
Q2 2023

Aug 14, 2023

BUY
$2.11 - $2.83 $54,378 - $72,934
25,772 New
25,772 $62,000
Q4 2022

Feb 14, 2023

BUY
$1.99 - $3.52 $187,601 - $331,837
94,272 Added 291.49%
126,613 $297,000
Q3 2022

Nov 14, 2022

SELL
$3.09 - $5.23 $209,693 - $354,918
-67,862 Reduced 67.72%
32,341 $100,000
Q2 2022

Aug 15, 2022

SELL
$2.58 - $4.99 $67 - $129
-26 Reduced 0.03%
100,203 $451,000
Q1 2022

May 16, 2022

SELL
$3.93 - $7.7 $794,767 - $1.56 Million
-202,231 Reduced 66.86%
100,229 $394,000
Q4 2021

Feb 14, 2022

BUY
$7.1 - $12.82 $944,747 - $1.71 Million
133,063 Added 78.55%
302,460 $2.15 Million
Q3 2021

Nov 15, 2021

BUY
$7.64 - $12.49 $697,088 - $1.14 Million
91,242 Added 116.74%
169,397 $1.86 Million
Q1 2021

May 17, 2021

BUY
$12.0 - $27.64 $388,668 - $895,231
32,389 Added 70.77%
78,155 $1.19 Million
Q2 2020

Aug 14, 2020

SELL
$9.75 - $17.6 $306,998 - $554,171
-31,487 Reduced 40.76%
45,766 $683,000
Q2 2019

Aug 14, 2019

BUY
$3.77 - $8.67 $218,151 - $501,689
57,865 Added 298.46%
77,253 $647,000
Q1 2019

May 15, 2019

SELL
$2.58 - $3.54 $163,192 - $223,915
-63,253 Reduced 76.54%
19,388 $0
Q2 2018

Aug 10, 2018

BUY
$0.92 - $3.5 $76,029 - $289,243
82,641 New
82,641 $0
Q1 2018

May 11, 2018

SELL
$1.38 - $2.33 $27,003 - $45,593
-19,568 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$1.63 - $2.0 $31,895 - $39,136
19,568
19,568 $37,000

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $27.3M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.